Recently, Iseda et al. reported that lenvatinib, which is another multiple tyrosine kinase inhibitor (TKI) and first-line treatment for HCC, downregulated the expression of SLC7A11 and induced ferroptosis in HCC cells [44]. This evidence concerns the gene SLC7A11 and hepatocellular carcinoma.